Valsartan Market In China PowerPoint PPT Presentations

Analyze Future: Hypertension Drugs Markets in China To get More Details @ http://www.analyzefuture.com/hypertension-drugs-in-china-market China's demand for Hypertension Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and 2013) and long-term forecasts through 2018 and 2023 are presented. Major producers in China are profiled.

Global Valsartan Report-Market Size and Forecast 2020 http://www.gosreports.com/global-valsartan-report-market-size-and-forecast-2020/

The price trend for Valsartan API in the North American region followed an increasing path in the second quarter of 2022. Healthy downstream pharmaceutical demand with lessened supply and reduced stocks with the suppliers affected the cost of Valsartan API further. During the second quarter, the market was volatile also due to protracted port congestion and a disrupted supply chain from China. Also, the trading activities were disrupted from various exporting countries resulting in higher freight charges and rerouting activity, positively impacting the price of Valsartan API. Also, manufacturing costs have risen in tandem with rising energy costs because of the recent rise in crude oil prices. Towards the end of the quarter, Valsartan prices were assessed at USD 143000/MT for CFR New York in June 2022.

Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control. Enquiry @ http://www.researchbeam.com/anti-hypertensive-therapeutics-in-asia-pacific-to-2021-increasing-prevalence-of-hypertension-drives-growth-despite-weak-pipeline-market/enquire-about-report

Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan.

Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control.

Title: PowerPoint Presentation Last modified by: xulei Created Date: 1/1/1601 12:00:00 AM Document presentation format: (4:3) Other titles

Results from the Akita register. Kazuo Suzuki ... of a stroke register set up in Akita to further understand stroke in Japan. ...

Valsartan (Angiotan or Diovan) is an angiotensin II receptor antagonist (more commonly called an ARB, or angiotensin receptor blocker), with particularly high affinity for the type I (AT1) angiotensin receptor. In December 1996, Valsartan was approved by FDA.